AR aberrations and resistance to abiraterone or enzalutamide
- 2 November 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Urology
- Vol. 13 (12), 697-698
- https://doi.org/10.1038/nrurol.2016.212
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate CancerEuropean Urology, 2017
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerJAMA Oncology, 2016
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate CancerJAMA Oncology, 2016
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate CancerThe Oncologist, 2016
- AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.Journal of Clinical Oncology, 2016
- Plasma AR and abiraterone-resistant prostate cancerScience Translational Medicine, 2015
- RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistanceScience, 2015
- Tumor clone dynamics in lethal prostate cancerScience Translational Medicine, 2014
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerThe New England Journal of Medicine, 2014
- Androgen Receptor Splice Variants in the Era of Enzalutamide and AbirateroneHormones and Cancer, 2014